127 related articles for article (PubMed ID: 31744877)
1. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
[TBL] [Abstract][Full Text] [Related]
2. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
Qiu Y; Bai L; Zhao H; Mei X
BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia.
Fisher-Wellman KH; Kassai M; Hagen JT; Neufer PD; Kester M; Loughran TP; Chalfant CE; Feith DJ; Tan SF; Fox TE; Ung J; Fabrias G; Abad JL; Sharma A; Golla U; Claxton DF; Shaw JJP; Bhowmick D; Cabot MC
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980769
[TBL] [Abstract][Full Text] [Related]
6. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Taori M; Horton BJ; Golla U; Sharma A; Szulc ZM; Wang HG; Chalfant CE; Cabot MC; Claxton DF; Loughran TP; Feith DJ
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136410
[TBL] [Abstract][Full Text] [Related]
7. Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function.
Ghazaly EA; Miraki-Moud F; Smith P; Gnanaranjan C; Koniali L; Oke A; Saied MH; Petty R; Matthews J; Stronge R; Joel SP; Young BD; Gribben J; Taussig DC
J Biol Chem; 2020 Apr; 295(16):5496-5508. PubMed ID: 32161116
[TBL] [Abstract][Full Text] [Related]
8. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
Ung J; Tan SF; Fox TE; Shaw JJ; Taori M; Horton BJ; Golla U; Sharma A; Szulc ZM; Wang HG; Chalfant CE; Cabot MC; Claxton DF; Loughran TP; Feith DJ
bioRxiv; 2023 Oct; ():. PubMed ID: 37961314
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.
Kao LP; Morad SAF; Davis TS; MacDougall MR; Kassai M; Abdelmageed N; Fox TE; Kester M; Loughran TP; Abad JL; Fabrias G; Tan SF; Feith DJ; Claxton DF; Spiegel S; Fisher-Wellman KH; Cabot MC
J Lipid Res; 2019 Sep; 60(9):1590-1602. PubMed ID: 31363040
[TBL] [Abstract][Full Text] [Related]
10. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
[TBL] [Abstract][Full Text] [Related]
11. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract][Full Text] [Related]
12. EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia.
Bill M; Pathmanathan A; Karunasiri M; Shen C; Burke MH; Ranganathan P; Papaioannou D; Zitzer NC; Snyder K; LaRocco A; Walker AE; Brannan ZJ; Nalin AP; Freud AG; Dikov MM; Zhang X; Bloomfield CD; Garzon R; Dorrance AM
Clin Cancer Res; 2020 Feb; 26(3):669-678. PubMed ID: 31672772
[TBL] [Abstract][Full Text] [Related]
13. The Expression of NTAL and Its Protein Interactors Is Associated With Clinical Outcomes in Acute Myeloid Leukemia.
Thomé CH; Ferreira GA; Pereira-Martins DA; Augusto Dos Santos G; Almeida-Silveira DR; Weinhäuser I; Antônio de Souza G; Houtsma R; Schuringa JJ; Rego EM; Faça VM
Mol Cell Proteomics; 2021; 20():100091. PubMed ID: 33971369
[TBL] [Abstract][Full Text] [Related]
14. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Stevens AM; Xiang M; Heppler LN; Tošić I; Jiang K; Munoz JO; Gaikwad AS; Horton TM; Long X; Narayanan P; Seashore EL; Terrell MC; Rashid R; Krueger MJ; Mangubat-Medina AE; Ball ZT; Sumazin P; Walker SR; Hamada Y; Oyadomari S; Redell MS; Frank DA
Blood Adv; 2019 Dec; 3(24):4215-4227. PubMed ID: 31856268
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia.
Cieniewicz B; Oliveira E; Saxton M; Torabi D; Bhatta A; Kukutla P; Arballo A; Yang Z; Yu B; Fate M; Ning H; Corey L; Maiti A; Corey D
Clin Cancer Res; 2024 May; 30(9):1878-1888. PubMed ID: 38451195
[TBL] [Abstract][Full Text] [Related]
16. Duocarmycin SA Reduces Proliferation and Increases Apoptosis in Acute Myeloid Leukemia Cells In Vitro.
Chen WA; Williams TG; So L; Drew N; Fang J; Ochoa P; Nguyen N; Jawhar Y; Otiji J; Duerksen-Hughes PJ; Reeves ME; Casiano CA; Jin H; Dovat S; Yang J; Boyle KE; Francis-Boyle OL
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673926
[TBL] [Abstract][Full Text] [Related]
17. Targeting inhibition of TCTP could inhibit proliferation and induce apoptosis in AML cells.
Xia D; Xu GP; Zhang YT; Yan WW; Pan XR; Tong JH
Cell Signal; 2024 May; 117():111074. PubMed ID: 38309549
[TBL] [Abstract][Full Text] [Related]
18. The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.
Su Y; Carter JL; Li X; Fukuda Y; Gray A; Lynch J; Edwards H; Ma J; Schreiner P; Polin L; Kushner J; Dzinic SH; Buck SA; Pruett-Miller SM; Hege-Hurrish K; Robinson C; Qiao X; Liu S; Wu S; Wang G; Li J; Allen JE; Prabhu VV; Schimmer AD; Joshi D; Kalhor-Monfared S; Watson IDG; Marcellus R; Isaac MB; Al-Awar R; Taub JW; Lin H; Schuetz JD; Ge Y
Cancer Res; 2024 Apr; 84(7):1084-1100. PubMed ID: 38266099
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A; Deshpande A; Feng Y; Finlay D; Lee JS; Lazar I; Fabre B; Li Y; Fujita Y; Zhang T; Yin J; Pass I; Livneh I; Jeremias I; Burian C; Mason JR; Almog R; Horesh N; Ofran Y; Brown K; Vuori K; Jackson M; Ruppin E; Deshpande AJ; Ronai ZA
Nat Commun; 2021 Sep; 12(1):5397. PubMed ID: 34518534
[TBL] [Abstract][Full Text] [Related]
20. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
